openPR Logo
Press release

Complicated Urinary Tract Infections (cUTIs) Market Poised for Extraordinary Growth During the Forecast Period (2023-32), Asserts DelveInsight | Allecra Therapeutics (EXBLIFEP (cefepime/enmetazobactam)), Iterum, Venatorx, Nabriva, Wockhardt, MerLion

02-28-2024 02:48 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Complicated Urinary Tract Infections (cUTIs) Market Poised

The Complicated Urinary Tract Infections (cUTIs) market is dynamically evolving with the development of novel antimicrobial agents, increased focus on antibiotic stewardship, and advancements in diagnostic technologies, offering the potential for more targeted and effective treatment options. Growing awareness of antibiotic resistance and the demand for alternative therapies are driving innovation and shaping the landscape of cUTI management, fostering improved patient outcomes.

DelveInsight's "Complicated Urinary Tract Infections (cUTIs) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Complicated Urinary Tract Infections Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Complicated Urinary Tract Infections therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Complicated Urinary Tract Infections treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Complicated Urinary Tract Infections (cUTIs): An Overview
Complicated Urinary Tract Infection (cUTI), a type of urinary tract infection (UTI) involving either the bladder or kidneys, is a symptomatic urinary infection that occurs in individuals with functional or structural abnormalities of the genitourinary tract, that predispose the patient to persistent infection, recurrent infection or treatment failure. UTIs are basically categorized as uncomplicated or complicated depending on the severity of infection. These are caused by a wide range of pathogens, including gram-negative and gram-positive bacteria as well as fungi.

Complicated UTIs occur when certain predisposing factors are present. These factors generally include obstructed urinary flow due to congenital causes, prostatic obstruction or urinary stones; incomplete bladder emptying due to anatomic (prostatic or urethral) or neurogenic (congenital or acquired spinal cord abnormalities) reasons; vesicoureteral reflux, foreign bodies in the urinary tract (instruments, catheters, drainage tubes); systemic illness such as diabetes; pregnancy and males participating in anal intercourse.

Complicated Urinary Tract Infections (cUTIs) Market Key Facts
• In 2021, the total Complicated Urinary Tract Infections (cUTIs) market size was USD 1,868.1 Million in the 7MM, which is expected to rise during the study period (2019-2032).
• The total Complicated Urinary Tract Infections (cUTIs) market size in the United States was USD 962.3 M in 2021.
• In EU-5, the total Complicated Urinary Tract Infections (cUTIs) market size was USD 642.0 M in 2021.
• In Japan, the Complicated Urinary Tract Infections (cUTIs) market size was USD 263.9 M in 2021.
• According to DelveInsight, in the year 2021, the total diagnosed incident cases of cUTI were 3.43 M in the United States.
• The highest number of total incident cases of cUTI was observed in Germany among the EU5 countries, with 0.87 M cases in 2021.
• In the year 2021, the total number of diagnosed incident cases of cUTI was 1.28 M in Japan.

Get a Detailed Overview of the Evolving Complicated Urinary Tract Infections Market Trends @
https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Complicated Urinary Tract Infections (cUTIs) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Complicated Urinary Tract Infections therapies in the market. It also provides a detailed assessment of the Complicated Urinary Tract Infections market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Complicated Urinary Tract Infections drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Complicated Urinary Tract Infections Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Complicated Urinary Tract Infections (cUTIs) Epidemiology
The epidemiology section covers detailed insights into the historical, and current Complicated Urinary Tract Infections patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Complicated Urinary Tract Infections Epidemiology Segmented as -
• Total Diagnosed-incident Cases of Complicated Urinary Tract Infection
• Total Age-specific Cases of Complicated Urinary Tract Infection
• Total Pathogen-specific Cases of Complicated Urinary Tract Infection
• Total Treated Cases (across lines) of Complicated Urinary Tract Infection

Get Key Insights Into the Evolving Complicated Urinary Tract Infections Epidemiology Trends @
https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Complicated Urinary Tract Infections (cUTIs) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Complicated Urinary Tract Infections market or expected to be launched during the study period. The analysis covers the market share by Complicated Urinary Tract Infections drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Complicated Urinary Tract Infections Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Complicated Urinary Tract Infections Market @
https://www.delveinsight.com/sample-request/complicated-urinary-tract-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Complicated Urinary Tract Infections (cUTIs) Therapeutics Assessment
The choice of treatment options for complicated UTIs depends on the severity of cUTI and encompasses three goals: management of the urological abnormality, antimicrobial therapy and supportive care when needed. Oral agents can be considered in patients who are clinically stable (either as initial therapy or as step-down therapy after IV). Trimethoprim-sulfamethoxazole and fluoroquinolones have excellent penetration into genitourinary tissue and are preferred oral agents for complicated UTI. Principles for treating recurrent complicated UTIs include early use of broad-spectrum antibiotics.

Recommended antibiotics options include fluoroquinolones, amoxicillin-clavulanate, third-generation cephalosporins with antipseudomonal activities, such as ceftazidime (Fortaz) or cefoperazone (Cefobid), cefepime (Maxipime), aztreonam (Azactam), imipenemcilastatin (Primaxin) or the combination of an antipseudomonal penicillin (ticarcillin, mezlocillin, piperacillin) with an aminoglycoside. Some of the approved antibiotics for cUTIs include ZEMDRI, Vabomere, Avycaz, Zerbaxa etc.

Several major pharma and biotech companies are actively developing therapies for Complicated Urinary Tract Infections. Currently, Spero Therapeutics is leading the therapeutics market with its Complicated Urinary Tract Infections drug candidates in the most advanced stage of clinical development.

On February 27, 2024, Allecra Therapeutics ("Allecra") announced that the US FDA has approved EXBLIFEP® (cefepime/enmetazobactam), as a treatment for complicated urinary tract infections (cUTIs), including pyelonephritis, in patients 18 years and older. Allecra has also received a five-year marketing exclusivity extension from the FDA as part of the Generating Antibiotic Incentives Now Act (GAIN Act). The GAIN Act, enacted by the U.S. Congress, incentivizes the creation of new anti-infective therapeutics by providing benefits to manufacturers of Qualified Infectious Disease Products (QIDPs).

Leading Companies in the Complicated Urinary Tract Infections (cUTIs) Therapeutics Market Include
• Spero Therapeutics
• Iterum Therapeutics
• Venatorx Pharmaceuticals, Inc.
• Nabriva Therapeutics
• Allecra Therapeutics
• Wockhardt
• MerLion Pharmaceuticals
And Many Others

Emerging and Marketed Complicated Urinary Tract Infections (cUTIs) Therapies Covered in the Report Include
• Tebipenem Pivoxil Hydrobromide: Spero Therapeutics
• Sulopenem: Iterum Therapeutics
• FEP-TAZ: Wockhardt
• Cefepime/AAI101 combination: Allecra
• S-649266: Shionogi
And Many More

Learn More About the Emerging Therapies and key Companies in the Complicated Urinary Tract Infections Therapeutics Market @
https://www.delveinsight.com/sample-request/complicated-urinary-tract-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Complicated Urinary Tract Infections Competitive Intelligence Analysis
4. Complicated Urinary Tract Infections Market Overview at a Glance
5. Complicated Urinary Tract Infections Background and Overview
6. Complicated Urinary Tract Infections Patient Journey
7. Complicated Urinary Tract Infections Epidemiology and Patient Population
8. Complicated Urinary Tract Infections Treatment Algorithm, Current Treatment, and Medical Practices
9. Complicated Urinary Tract Infections Unmet Needs
10. Key Endpoints of Complicated Urinary Tract Infections Treatment
11. Complicated Urinary Tract Infections Marketed Products
12. Complicated Urinary Tract Infections Emerging Therapies
13. Complicated Urinary Tract Infections Seven Major Market Analysis
14. Attribute Analysis
15. Complicated Urinary Tract Infections Market Outlook (7 major markets)
16. Complicated Urinary Tract Infections Access and Reimbursement Overview
17. KOL Views on the Complicated Urinary Tract Infections Market.
18. Complicated Urinary Tract Infections Market Drivers
19. Complicated Urinary Tract Infections Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/complicated-urinary-tract-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Complicated Urinary Tract Infections (cUTIs) Market Poised for Extraordinary Growth During the Forecast Period (2023-32), Asserts DelveInsight | Allecra Therapeutics (EXBLIFEP (cefepime/enmetazobactam)), Iterum, Venatorx, Nabriva, Wockhardt, MerLion here

News-ID: 3403822 • Views:

More Releases from DelveInsight Business Research LLP

Urothelial Carcinoma Pipeline Outlook Report 2024 (Updated)
Urothelial Carcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Urothelial Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 40+ Urothelial Carcinoma companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape. It covers the Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Urothelial Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways
EGFR Non-Small Cell Lung Cancer Pipeline Outlook Report 2024 (Updated)
EGFR Non-Small Cell Lung Cancer Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insights 2024" report provides comprehensive insights about 40+ EGFR Non-Small Cell Lung Cancer companies and 42+ pipeline drugs in the EGFR Non-Small Cell Lung Cancer pipeline landscape. It covers the EGFR Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the EGFR Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage,
Follicular Lymphoma Pipeline Outlook Report 2024 (Updated)
Follicular Lymphoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Follicular Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 50+ Follicular Lymphoma companies and 50+ pipeline drugs in the Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Follicular Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways
Recurrent Glioblastoma Pipeline Outlook Report 2024 (Updated)
Recurrent Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Recurrent Glioblastoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Recurrent Glioblastoma Pipeline Report DelveInsight's Recurrent Glioblastoma

All 5 Releases


More Releases for Complicated

Starting an online fashion retail business need not be complicated
The problem is that of perception. There is always a needless, negative hype in the air that starting an online fashion retail business ( https://www.yourretailcoach.in/fashion-digital-marketing-agency-india/ ) and being successful at it is a tough game and not meant for everyone. Not all industry experts or retail consultants believe in such limiting and damping conclusions. Despite the challenges, there are businesses that keep coming and are also able to hold their
Identity Analytics- An Innovative Tech to Automate Complicated Identity Based Co …
With top-end technological advancements on board, lagging behind even on a single aspect may lead a business venture to lose the battle. Especially, in a scenario, when every emergent, as well as an established company, is hell-bent on proving their excellence in their respective domains, lacking even in a single facet can prove to be fatal for their repute. Identity analytics is one of such technologies that is dominating the
Complicated Unmet Dental Needs of Aged Create Demand for CBCT Technologies
The trend in the global cone beam computed tomography (CBCT) indicates that players must invest in developing countries to cater to consumers’ unmet medical demands and attain bigger revenue shares, says Transparency Market Research in a new report. Danaher, Planmeca, and Sirona jointly held a massive share of 70% in the global market in 2015.   Analysts have identified Asia Pacific as the most promising region for growth in the coming few years. Furthermore,
Global Aptamers Market in a complicated way by Market Data Forecast.
According to the report “Global Aptamers Market", published by Market Data Forecast, the global market is projected to reach USD 293 million by 2021, at a CAGR of 18.0% from 2016 to 2021. For full report refer to : http://www.marketdataforecast.com/market-reports/global-aptamers-market-1134/ Aptamers are oligonucleotides which bind to target lipid, protein or nucleic acid molecules with a high specificity. Aptamers are generally applied in the inhibition and generated rapidly, characterization of proteins and
Complicated Skin And Skin Structure Infections (cSSSI)-Pipeline Insights, 2017
Orbis Research delivers key insights on the global Complicated Skin And Skin Structure Infections (cSSSI) market in a new report titled “Complicated Skin And Skin Structure Infections (cSSSI)-Pipeline Insights, 2017” In this report, Orbis Research sheds light on the various factors and trends impacting market growth over the forecast period (2017 – 2022). “Complicated Skin And Skin Structure Infections (cSSSI)-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs
Prevalence of Complicated Urinary Tract Infection (UTI) to Increase Globally
Over 60% physicians are likely to prescribe penicillin and combinations to treat urinary tract infections (UTIs), whereas a vast majority prescribe quinolones in their daily practice to treat complicated cases. A significant percentage of physicians also agreed that they prescribed nitrofurans to treat uncomplicated urinary tract infections in female patients. FMI’s survey also found that cephalosporin is the second-most common drug in the treatment of recurrent and complicated urinary tract